[Cabergoline in hyperprolactinemia and valvular heart disease]. 2009

Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
Servicio de Endocrinología y Nutrición, Hospital Infanta Sofía, San Sebastián de los Reyes, Madrid, España. marcos.lahera@salud.madrid.org

BACKGROUND High-dose cabergoline therapy has been related to cardiac valve regurgitation in patients with Parkinson's disease. OBJECTIVE To perform a systematic analysis of reports on low-dose cabergoline treatment in hyperprolactinemia and its effect on the cardiac valves. RESULTS None of the seven reports analyzed, including 463 patients in total, found clinically significant valve regurgitation. Only one report found moderate tricuspid valve regurgitation, and other two reports found mild tricuspid valve regurgitation. An increase in the mitral tenting area was documented in only one of two reports. Valve thickening and calcifications were found in only one study. CONCLUSIONS Cabergoline seems to be safe at the doses employed in hyperprolactinemic patients. There is a higher prevalence of tricuspid regurgitation, detected by systematic echocardiography, but this abnormality is asymptomatic. Although prospective longitudinal studies are needed, vigilance of these patients is recommended, especially those treated with high-dose cabergoline.

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D005260 Female Females
D006349 Heart Valve Diseases Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE). Heart Valvular Disease,Valvular Heart Diseases,Disease, Heart Valvular,Heart Disease, Valvular,Heart Valve Disease,Heart Valvular Diseases,Valve Disease, Heart,Valvular Disease, Heart,Valvular Heart Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077465 Cabergoline An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE. 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea,1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate,Cabaser,Cabaseril,Cabergoline Diphosphate,Dostinex,FCE 21336,FCE-21336,Galastop

Related Publications

Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
September 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
January 2007, ACP journal club,
Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
June 1997, The Medical letter on drugs and therapeutics,
Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
May 2013, Revista espanola de cardiologia (English ed.),
Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
July 2017, Endocrine,
Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
January 2009, Clinical endocrinology,
Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
January 2010, Expert review of cardiovascular therapy,
Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
April 2009, Internal medicine journal,
Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
July 2008, Rinsho shinkeigaku = Clinical neurology,
Marcos Lahera Vargas, and Carlos Escobar Cervantes, and Carmen Alameda Hernando, and César Varela Da Costa
February 2020, BMC endocrine disorders,
Copied contents to your clipboard!